AnaptysBio, Inc.
ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF
Last updated:
Abstract:
The disclosure provides antibody agents that bind to a Lymphocyte Activation Gene-3 (LAG-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using anti-LAG-3 antibody agents to treat a disorder or disease that is responsive to LAG-3 inhibition, such as, for example, cancer or an infectious disease.
Status:
Application
Type:
Utility
Filling date:
27 Apr 2018
Issue date:
5 May 2022